金水焕纤颗粒治疗特发性肺纤维化的疗效与安全性:多中心、随机、双盲、安慰剂对照试验的研究方案
本研究为多中心、随机、双盲、安慰剂对照临床试验,计划纳入312例特发性肺纤维化患者,按1:1随机分为金水焕纤颗粒(JHG)组和JHG安慰剂组。经过2周洗脱期后,所有患者接受52周治疗,评估急性加重、肺功能、呼吸困难、运动能力和生活质量等指标。基于既往研究,假设JHG可减少急性加重、改善运动能力、肺功能和生活质量,并延缓疾病无进展生存,同时为中医药治疗特发性肺纤维化提供高级别循证证据。
要点
- 多中心、随机、双盲、安慰剂对照试验,计划纳入312例特发性肺纤维化患者,1:1随机分组。
- 经过2周洗脱期后,所有患者接受52周治疗,试验组给予金水焕纤颗粒,对照组给予金水焕纤颗粒安慰剂。
- 主要评估指标包括急性加重、肺功能、呼吸困难、运动能力和生活质量。
核心结论
- 基于既往研究,假设金水焕纤颗粒可减少急性加重、改善运动能力、肺功能和生活质量,并延缓疾病无进展生存。
- 本研究将为中医药治疗特发性肺纤维化提供高级别循证支持。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照临床试验。
- 计划纳入312例特发性肺纤维化患者,按1:1随机分配至两组。
- 经过2周洗脱期后,所有患者接受52周治疗,试验组给予金水焕纤颗粒,对照组给予金水焕纤颗粒安慰剂。
关键数值与推荐
- 评估指标包括急性加重、肺功能、呼吸困难、运动能力和生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND RATIONALE: Idiopathic pulmonary fibrosis is a critical disease with a poor prognosis. Although different studies have been conducted for the treatment of idiopathic pulmonary fibrosis, limited treatments are available. Jin-shui Huan-xian granule (JHG), which is a Chinese medicine herbal compound, has shown promising efficacy in reducing frequencies of acute exacerbations, improving exercise capacity the quality of life of patients with idiopathic pulmonary fibrosis. This study is to evaluate the efficacy and safety of JHG for IPF. SUBJECTS AND METHODS: This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 312 idiopathic pulmonary fibrosis patients will be enrolled and randomly allocated to one of the two groups with 1:1. After a 2-week washout period, 52-week treatment will also be performed for all the patients. Patients in the experimental group and the control group will be given JHG and JHG placebo, respectively. Outcome measures including acute exacerbations, pulmonary function, dyspnea, exercise capacity, and quality of life will be evaluated in this study. DISCUSSION: Based on our previous study, it is hypothesized that JHG will reduce acute exacerbations; improve exercise capacity, pulmonary function, and quality of life; and delay the disease progression-free. High-level evidence-based support for TCM in IPF will also be obtained in this study. TRIAL REGISTRATION: ClinicalTrials.gov NCT04187690. Register on December 11, 2019.
引用
- Yang SG, Yu XQ, Li JS, et al. Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. Trials. 2022. PMID: 36056382. doi:10.1186/s13063-022-06684-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。